ライフサイエンスコーパス: systemic arterial pressure

1 continuous monitoring of cardiac output and systemic arterial pressure.

2 arterial muscularization with no increase in systemic arterial pressure.

3 ht ventricular dysfunction despite preserved systemic arterial pressure.

4 O exceeds that from phenylephrine at matched systemic arterial pressure.

5 ns of AngII caused dose-related increases in systemic arterial pressure.

6 flow in both rat strains, without affecting systemic arterial pressure.

7 n of pulmonary hypertension without reducing systemic arterial pressure.

8 tening, even at a dose that did not increase systemic arterial pressure.

9 nd well tolerated, even by patients with low systemic arterial pressure.

10 continuous monitoring of cardiac output and systemic arterial pressure.

11 Milrinone had no effect on heart rate or systemic arterial pressure.

12 s thermal adaptation, exercise capacity, and systemic arterial pressure.

13 was maintained at 20 mmHg while maintaining systemic arterial pressures.

14 Systemic arterial pressure (108.2 +/- 1.4 mm Hg) was una

15 Sildenafil caused a modest decrease in mean systemic arterial pressure (-11%; P<0.001) but was well

16 output 58% +/- 1% of baseline), hypotension (systemic arterial pressure 31 +/- 1 mm Hg), and acidosis

17 up had a significantly (p = 0.01) lower mean systemic arterial pressure (80.1 +/- 15.1 mm Hg) versus

18 gnificant vs. inhaled nitric oxide), whereas systemic arterial pressure and cardiac output again rema

19 ressure from 33 to 21 torr (p <.01), whereas systemic arterial pressure and cardiac output were uncha

20 Immediately after implantation, systemic arterial pressure and stroke volume increased a

21 D) CPR, ITPR-CPR will enhance venous return, systemic arterial pressure, and vital organ perfusion in

22 of the circuit for monitoring the simulated systemic arterial pressure; and d) at the reservoir.

23 UcnII also reduced systemic arterial pressure, associated with a lowering o

24 h as 9 mmHg with no observable effect on the systemic arterial pressure at an infusion rate of up to

25 difference in pulmonary arterial pressure or systemic arterial pressure at any time between untreated

26 ration of DTPA iron (III) did not alter mean systemic arterial pressure, but did protect baboons in t

27 nal blood flow and GFR were not sustained as systemic arterial pressure decreased.

28 ratio of maximal intracavernosal pressure to systemic arterial pressure from 0.49 +/- 0.03 to 0.41 +/

29 s of cerebral artery blood flow velocity and systemic arterial pressure in 15 patients who did or did

30 he present results suggest that increases in systemic arterial pressure in response to AngII in the a

31 ) and PD123319 (10 mg/kg i.v.) on changes in systemic arterial pressure in response to angiotensin II

32 ive type II NOS antagonists increase PVR and systemic arterial pressure in the late-gestation fetus.

33 data include electrocardiogram, respiration, systemic arterial pressure (invasive and noninvasive), c

34 us inotropic or pressor agents or a low mean systemic arterial pressure (<60 mm Hg).

35 ation of chest pain, we measured heart rate, systemic arterial pressure, LV pressure and its first de

36 Mean pulmonary (MPAP) and mean systemic arterial pressures (MAP), atrial pressures, car

37 rial pressure (MPAP), it also decreased mean systemic arterial pressure (MSAP).

38 o 33 torr) while not significantly affecting systemic arterial pressure or cardiac output.

39 D123319 had a significant effect on baseline systemic arterial pressure or on the increase in arteria

40 ion in pulmonary artery pressure (P[PA]) and systemic arterial pressure (P[SA]).

41 ted and instrumented for measurement of mean systemic arterial pressure, pulmonary arterial pressure,

42 ere anesthetized and instrumented to monitor systemic arterial pressure, pulmonary artery pressure, a

43 monary vascular resistance, and pulmonary-to-systemic arterial pressure ratio resolved the observed s

44 was higher and the pulmonary artery pressure/systemic arterial pressure ratio was lower in doxycyclin

45 There was no change in systemic arterial pressure throughout the studies.

46 arotid arteries and hemorrhage to reduce the systemic arterial pressure to about 40 mmHg), followed b

47 supply most often due to a transient fall of systemic arterial pressure to levels below those tolerat

48 ch group with nitroprusside, but the drop in systemic arterial pressure was 2.6-fold greater in HFpEF

49 Systemic arterial pressure was higher and the pulmonary

50 A compensatory increase in systemic arterial pressure was observed in rats treated

51 ore, and pulmonary vascular resistance while systemic arterial pressure was stabilized.

52 High-fidelity systemic arterial pressure waveforms, from ascending aor

53 n to determine whether it could help improve systemic arterial pressures when fluid replacement was n

54 control element of both tissue perfusion and systemic arterial pressure, with potential implications